ArticlePLoS neglected tropical diseases2020
Identification and detection of a novel point mutation in the Chitin Synthase gene of Culex pipiens associated with diflubenzuron resistance.
Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Allelic Survey and Population Genomics in a Hotspot of Diflubenzuron Resistance in the MosquitoInsects · 2026Article
- Insecticide resistance in mosquitoes: Current status, mechanism, monitoring and innovative strategies for sustainable vector control.Molecular biology reports · 2026Review
- Disruption of chitin synthases impairs tick feeding and reproduction, validating a broad-spectrum acaricide target.Frontiers in cellular and infection microbiology · 2026Article
- GC/MS analysis and insecticidal activity of Pelargonium graveolens essential oil from Algeria against Culex pipiens and Culiseta longiareolata mosquito larvae.Die Naturwissenschaften · 2025Article
- Mechanisms and Genetic Drivers of Resistance of Insect Pests to Insecticides and Approaches to Its Control.Toxics · 2025Review
- First report and evidence of multiple origins of diflubenzuron resistance alleles in Culex pipiens mosquito from Cyprus.Parasites & vectors · 2025Article
- Article
- Comparative transcriptomics reveals different profiles between diflubenzuron-resistant and -susceptible phenotypes of the mosquito Culex pipiens.Pest management science · 2025Article
- Widespread Distribution ofInsects · 2025Article
- Integrated de novo transcriptome of Culex pipiens mosquito larvae as a resource for genetic control strategies.Scientific data · 2024Article
- Article
- Aedes aegypti CCEae3A carboxylase expression confers carbamate, organophosphate and limited pyrethroid resistance in a model transgenic mosquito.PLoS neglected tropical diseases · 2024Article
- Article
- Cuticle Modifications and Over-Expression of the Chitin-Synthase Gene in Diflubenzuron-Resistant Phenotype.Insects · 2022Article
- Characterization of Chitin Synthase A cDNA fromInsects · 2022Article
- Historical samples reveal a combined role of agriculture and public-health applications in vector resistance to insecticides.Pest management science · 2022Article
- Mosquito population structure, pathogen surveillance and insecticide resistance monitoring in urban regions of Crete, Greece.PLoS neglected tropical diseases · 2022Article
- West Nile virus transmission potential in Portugal.Communications biology · 2022Article
- Insecticide resistance to insect growth regulators, avermectins, spinosyns and diamides in Culex quinquefasciatus in Saudi Arabia.Parasites & vectors · 2021Article
- Effects of Selection to Diflubenzuron andInsects · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiflubenzuron (DFB) is one of the most used insecticides in mosquito larval control including that of Culex pipiens, the proven vector of the recent West Nile Virus epidemics in Europe. Two mutations (I1043L and I1043M) in the chitin synthase (CHS) putative binding site of DFB have been previously reported in Cx. pipiens from Italy and associated with high levels of resistance against this larvicide. METHODOLOGY/PRINCIPAL
findingsHere we report the identification of a third mutation at the same I1043 position of the CHS gene resulting in the substitution of Isoleucine to Phenylalanine (I1043F). This mutation has also been found in agricultural pests and has been functionally validated with genome editing in Drosophila, showing to confer striking levels (>15,000 fold) of DFB resistance. The frequency of the I1043F mutation was found to be substantially higher in Cx. pipiens mosquitoes surviving DFB doses largely exceeding the recommended field dose, raising concerns about the future efficient use of this insecticide. We monitored the presence and frequency of DFB mutations in Cx. pipiens mosquitoes from several Mediterranean countries, including Italy, France, Greece, Portugal and Israel. Among the Cx. pipiens populations collected in Northern Italy all but one had at least one of the three DFB mutations at allele frequencies reaching 93.3% for the I1043M, 64.8% for the I1043L and 10% for the I1043F. The newly reported I1043F mutation was also identified in two heterozygote individuals from France (4.2% allelic frequency). In contrast to Italy and France, no DFB resistant mutations were identified in the Cx. pipiens mosquitoes sampled from Greece, Portugal and Israel. CONCLUSIONS/SIGNIFICANCE: The findings of our study are of major concern for mosquito control programs in Europe, that rely on the use of a limited number of available larvicides, and highlight the necessity for the development of appropriate Insecticide Resistance Management (IRM) programs, to ensure the sustainable use of DFB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.